drugset / Trial / NCT07733245
Efficacy and Safety of HRS-9190 in General Anesthesia
Phase 3
Enrolling by invitation
320 enrolled
The Third Xiangya Hospital of Central South University
Jiangsu Hengrui Pharmaceutical Co., Ltd. · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
A multicenter, randomized, double - blind, placebo - controlled, parallel - group phase III clinical trial was carried out to evaluate the efficacy and safety of HRS - 9190 for skeletal muscle relaxation during tracheal intubation in the induction and maintenance phases of general anesthesia. The primary objective was to evaluate the effectiveness of HRS - 9190 in achieving skeletal muscle relaxation during tracheal intubation in the induction and maintenance phases of general anesthesia. The secondary objective was to assess the safety and pharmacokinetic profile of HRS - 9190.
Timeline
- Start
- 2026-09-02
- Primary completion
- 2026-12-31
- Completion
- 2027-03-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | HRS-9190 | Unknown | 0.2 mg/kg | Intravenous |
| Comparator | Rocuronium | Other / unclassified | 0.15 mg/kg | Intravenous |
Indications
No indication recorded.